Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy

BORAN, Nurettin; TULUNAY, Gökhan; TURAN, Taner; Meydanli, Mehmet Mutlu; DÜZGÜNER, İpek; bas, sevda; Selcuk, ilker; Alkan, Afra

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy

İlker SELÇUK, (Boş)

İpek DÜZGÜNER, (Boş)

Sevda BAŞ, (Boş)

Taner TURAN, (Boş)

Afra ALKAN, (Boş)

Nurettin BORAN, (Boş)

Mehmet Mutlu MEYDANLI, (Boş)

Gökhan TULUNAY (Boş)

GORM:Gynecology Obstetrics & Reproductive Medicine

4 1

Yıl: 2015 Cilt: 21 Sayı: 1 Sayfa Aralığı: 36 - 40 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy

Öz:

AMAÇ: Overyan karsinosarkomlu hastaların platin veya dok- sorubisin bazlı adjuvan kemoterapi protokolüne bağlı olarak sağ kalım analizini yapmak. GEREÇ VE YÖNTEM: Bu retrospektif çalışma Türkiyede ter- siyer merkezler olan Etlik Zübeyde Hanım ve Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanelerinde yapılmıştır. Ocak 1999 ve Ocak 2013 tarihler arasında tanı alan 31 olgu in- celenmiştir. BULGULAR: Hastaların ortalama yaşı 53,84±10,13 dir. Çoğu hasta Evre IIIC over karsinosarkomu ile tanı almıştır (%67,7). Yirmiüç (%74,2) hastaya maksimal tümör indirgeme cerrahisi, 8 (%25,8) hastaya ise optimal tümör indirgeme cerrahisi yapıl- mıştır. Evre IIIC hastalarda hastalıksız sağ kalım Evre IIIB has- talara göre kısa bulunmuştur (p=0,048). Bir ve üç yıllık hasta- lıksız sağ kalımlar platin veya doksorubisin kemoterapisi alan hastalar arasında farklı olarak bulunmamıştır (p=0,574). Aynı zamanda üç ve beş yıllk kaba sağ kalım süreleri de platin ve- ya doksorubisin kemoterapileri alan hasta grupları arasında farklı değildir (p=0,891). SONUÇ: Overyan karsinosarkomlu hastalarda platin veya dok- sorubisin bazlı adjuvan kemoterapi protokolü arasında hasta- lıksız sağ kalım ve kaba sağ kalım açısından anlamlı bir farklı- lık yoktur.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Hematoloji Onkoloji

Overyan Karsinosarkom Hastalarının Platin veya Doksorubisin Bazlı Adjuvan Kemoterapi Protokolüne Bağlı Olarak Sağ Kalım Analizi

Öz:

OBJECTIVE: To analyse the survival outcomes of women with ovarian carcinosarcoma according to platinum or doxorubicin based adjuvant chemotherapy protocols. STUDY DESIGN: This retrospective study was performed at Etlik Zübeyde Hanım and Zekai Tahir Burak Women s Health Education and Research Hospitals, which are tertiary centers in Turkey. A total of 31 women with ovarian carcinosarcoma between January 1999 and January 2013 were evaluated retro- spectively. RESULTS: The mean age of patients was 53.84±10.13. Most of the patients were diagnosed with stage IIIC ovarian carcinosarcoma (n=21, 67.7%). Maximal debulking and optimal debulking was performed to 23 (74.2%) and 8 (25.8%) patients, respectively. Disease free survival was significantly shorter in stage IIIC patients when compared to stage IIIB patients (p=0.048). Disease free survival for one and three years according to the treatment protocol (platinum or doxorubicin based) was not significantly different (p=0.574). Additionally, three and five years overall survival was not significantly different (p=0.891) be- tween the platinum and doxorubicin based chemotherapy protocols. DISCUSSION: We did not find a significant difference in terms of disease free survival and overall sur- vival between platinum and doxorubicin based adjuvant chemotherapy protocols in women with ovarian carcinosarcoma.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Hematoloji Onkoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

SONUÇ: Overyan karsinosarkomlu hastalarda platin veya dok- sorubisin bazlı adjuvan kemoterapi protokolü arasında hasta- lıksız sağ kalım ve kaba sağ kalım açısından anlamlı bir farklı- lık yoktur. ovary: experience with surgical cytoreduction and combi- nation chemotherapy. Cancer. 1995 Oct 1;76(7):1209-13. 13. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, et al. Malignant mixed mullerian tumors of the ovary: ex- perience with cytoreductive surgery and platinum-based combination chemotherapy. International journal of gyne- cological cancer: official journal of the International Gynecological Cancer Society. 2006 Jan-Feb;16 (1):101-5. 14. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memo- rial Sloan-Kettering Cancer Center experience. Gynecologic oncology. 2007 Jun; 105(3):657-61. 15. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 1995 Oct;6(8):755-8. 16. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for ma- lignant mixed mullerian tumors of the ovary. Gynecologic oncology 2002 Jun;85(3):459-63. 17. Jernigan AM, Fader AN, Nutter B, Rose P, Tseng JH, Escobar PF. Ovarian carcinosarcoma: effects of cytore- ductive status and platinum-based chemotherapy on sur- vival. Obstetrics and gynecology international 2013; 2013: 490508. PubMed PMID: 23781249. 18. Morrow CP, Bundy BN, Hoffman J, Sutton G, Homesley H. Adriamycin chemotherapy for malignant mixed meso- dermal tumor of the ovary. A Gynecologic Oncology Group Study. American journal of clinical oncology 1986 Feb;9(1):24-6. 19. Sutton GP, Blessing JA, Homesley HD, Malfetano JH. A phase II trial of ifosfamide and mesna in patients with ad- vanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemother- apy: a Gynecologic Oncology Group study. Gynecologic oncology. 1994 Apr;53(1):24-6. 20. Gomez-Raposo C, Lopez-Gomez M, Sereno M, Zambrana F, Casado E. Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of as- sessment of the response by FDG-PET. Gynecologic on- cology case reports 2012;2(2):67-8. PubMed PMID: 24371621. 21. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carci- nosarcomas of the uterus. Gynecologic oncology. 2010 May;117(2):248-54.

APA	Selcuk i, DÜZGÜNER İ, bas s, TURAN T, Alkan A, BORAN N, Meydanli M, TULUNAY G (2015). Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. , 36 - 40.
Chicago	Selcuk ilker,DÜZGÜNER İpek,bas sevda,TURAN Taner,Alkan Afra,BORAN Nurettin,Meydanli Mehmet Mutlu,TULUNAY Gökhan Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. (2015): 36 - 40.
MLA	Selcuk ilker,DÜZGÜNER İpek,bas sevda,TURAN Taner,Alkan Afra,BORAN Nurettin,Meydanli Mehmet Mutlu,TULUNAY Gökhan Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. , 2015, ss.36 - 40.
AMA	Selcuk i,DÜZGÜNER İ,bas s,TURAN T,Alkan A,BORAN N,Meydanli M,TULUNAY G Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. . 2015; 36 - 40.
Vancouver	Selcuk i,DÜZGÜNER İ,bas s,TURAN T,Alkan A,BORAN N,Meydanli M,TULUNAY G Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. . 2015; 36 - 40.
IEEE	Selcuk i,DÜZGÜNER İ,bas s,TURAN T,Alkan A,BORAN N,Meydanli M,TULUNAY G "Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy." , ss.36 - 40, 2015.
ISNAD	Selcuk, ilker vd. "Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy". (2015), 36-40.

APA	Selcuk i, DÜZGÜNER İ, bas s, TURAN T, Alkan A, BORAN N, Meydanli M, TULUNAY G (2015). Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. GORM:Gynecology Obstetrics & Reproductive Medicine, 21(1), 36 - 40.
Chicago	Selcuk ilker,DÜZGÜNER İpek,bas sevda,TURAN Taner,Alkan Afra,BORAN Nurettin,Meydanli Mehmet Mutlu,TULUNAY Gökhan Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. GORM:Gynecology Obstetrics & Reproductive Medicine 21, no.1 (2015): 36 - 40.
MLA	Selcuk ilker,DÜZGÜNER İpek,bas sevda,TURAN Taner,Alkan Afra,BORAN Nurettin,Meydanli Mehmet Mutlu,TULUNAY Gökhan Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. GORM:Gynecology Obstetrics & Reproductive Medicine, vol.21, no.1, 2015, ss.36 - 40.
AMA	Selcuk i,DÜZGÜNER İ,bas s,TURAN T,Alkan A,BORAN N,Meydanli M,TULUNAY G Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. GORM:Gynecology Obstetrics & Reproductive Medicine. 2015; 21(1): 36 - 40.
Vancouver	Selcuk i,DÜZGÜNER İ,bas s,TURAN T,Alkan A,BORAN N,Meydanli M,TULUNAY G Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. GORM:Gynecology Obstetrics & Reproductive Medicine. 2015; 21(1): 36 - 40.
IEEE	Selcuk i,DÜZGÜNER İ,bas s,TURAN T,Alkan A,BORAN N,Meydanli M,TULUNAY G "Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy." GORM:Gynecology Obstetrics & Reproductive Medicine, 21, ss.36 - 40, 2015.
ISNAD	Selcuk, ilker vd. "Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy". GORM:Gynecology Obstetrics & Reproductive Medicine 21/1 (2015), 36-40.